A Systematic Review of Maternal Serum Syndecan-1 and Preeclampsia

Kitty George, Prakar Poudel, Roopa Chalasani, Mastiyage R Goonathilake, Sara Waqar, Sheeba George, Wilford Jean-Baptiste, Amina Yusuf Ali, Bithaiah Inyang, Feeba Sam Koshy, Lubna Mohammed, Kitty George, Prakar Poudel, Roopa Chalasani, Mastiyage R Goonathilake, Sara Waqar, Sheeba George, Wilford Jean-Baptiste, Amina Yusuf Ali, Bithaiah Inyang, Feeba Sam Koshy, Lubna Mohammed

Abstract

Exploration of novel biomarkers has been gaining popularity in preeclampsia, which is currently being diagnosed based on clinical criteria alone. Soluble syndecan-1, released from one of the proteoglycans associated with the syncytiotrophoblastic layer of the placenta, is affected in patients with abnormal placentation. This article is the first systematic literature review that evaluates the relationship between the antepartum serum levels of the syndecan-1 and preeclampsia. Eight studies were selected after screening and quality appraisal, and data were analyzed. The serum concentration of syndecan-1 was found to correlate positively with the gestational age in all pregnancies and negatively with the systolic blood pressure in patients with preeclampsia. Extremely low levels of soluble syndecan-1 may be helpful as a predictor for the development of preeclampsia during gestation.

Keywords: cd-138; eph complex; preeclampsia; sdc-1; syndecan-1.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2022, George et al.

Figures

Figure 1. Flow diagram of study selection
Figure 1. Flow diagram of study selection
PMC: PubMed Central; BASE: Bielefeld Academic Search Engine. Created using Lucidchart (Lucid Software Inc., South Jordan, UT).
Figure 2. Shedding of transmembrane syndecan-1 and…
Figure 2. Shedding of transmembrane syndecan-1 and formation of soluble syndecan-1
Created using Microsoft Paint 3D (Microsoft Corporation, Redmond, WA) by George Michael.

References

    1. The global impact of pre-eclampsia and eclampsia. Duley L. Semin Perinatol. 2009;33:130–137.
    1. Preeclampsia—pathophysiology and clinical presentations: JACC state-of-the-art review. Ives CW, Sinkey R, Rajapreyar I, Tita AT, Oparil S. J Am Coll Cardiol. 2020;76:1690–1702.
    1. Hypertensive disorders of pregnancy. Wilkerson RG, Ogunbodede AC. Emerg Med Clin North Am. 2019;37:301–316.
    1. Epidemiology of preeclampsia: impact of obesity. Jeyabalan A. Nutr Rev. 2013;71:0–25.
    1. The placenta in preeclampsia. Roberts JM, Escudero C. Pregnancy Hypertens. 2012;2:72–83.
    1. Management of pre-eclampsia. Duley L, Meher S, Abalos E. BMJ. 2006;332:463–468.
    1. Antiplatelet agents and the prevention of spontaneous preterm birth: a systematic review and meta-analysis. van Vliet EO, Askie LA, Mol BW, Oudijk MA. Obstet Gynecol. 2017;129:327–336.
    1. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Aust N Z J Obstet Gynaecol. 1995;35:357–362.
    1. Evidence-based prevention of preeclampsia: commonly asked questions in clinical practice. Wertaschnigg D, Reddy M, Mol BW, da Silva Costa F, Rolnik DL. J Pregnancy. 2019;2019:2675101.
    1. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. Rolnik DL, Wright D, Poon LC, et al. N Engl J Med. 2017;377:613–622.
    1. Placenta-derived exosomes: potential biomarkers of preeclampsia. Pillay P, Moodley K, Moodley J, Mackraj I. Int J Nanomedicine. 2017;12:8009–8023.
    1. Novel biomarkers for predicting preeclampsia. Carty DM, Delles C, Dominiczak AF. Trends Cardiovasc Med. 2008;18:186–194.
    1. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. Zeisler H, Llurba E, Chantraine F, et al. N Engl J Med. 2016;374:13–22.
    1. Clinical applications of biomarkers in preeclampsia. Griffin M, Shennan AH. Biomark Med. 2014;8:459–470.
    1. The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Szatmári T, Dobra K. Front Oncol. 2013;3:310.
    1. Syndecan-1 acts as an important regulator of CXCL1 expression and cellular interaction of human endometrial stromal and trophoblast cells. Baston-Buest DM, Altergot-Ahmad O, Pour SJ, Krüssel JS, Markert UR, Fehm TN, Bielfeld AP. Mediators Inflamm. 2017;2017:8379256.
    1. Functions of cell surface heparan sulfate proteoglycans. Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Annu Rev Biochem. 1999;68:729–777.
    1. Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5. Hayashida K, Stahl PD, Park PW. J Biol Chem. 2008;283:35435–35444.
    1. Heparanase-enhanced shedding of syndecan-1 and its role in driving disease pathogenesis and progression. Rangarajan S, Richter JR, Richter RP, Bandari SK, Tripathi K, Vlodavsky I, Sanderson RD. J Histochem Cytochem. 2020;68:823–840.
    1. Soluble syndecan-1 as marker of intestinal inflammation: a preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis. Floer M, Clausen M, Meister T, Vollenberg R, Bettenworth D, Tepasse PR. Adv Clin Exp Med. 2021;30:655–660.
    1. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Day R, Ilyas M, Daszak P, Talbot I, Forbes A. Dig Dis Sci. 1999;44:2508–2515.
    1. Serum syndecan-1 reflects organ dysfunction in critically ill patients. Suzuki K, Okada H, Sumi K, et al. Sci Rep. 2021;11:8864.
    1. Syndecan-1 in cancer: implications for cell signaling, differentiation, and prognostication. Szatmári T, Ötvös R, Hjerpe A, Dobra K. Dis Markers. 2015;2015:796052.
    1. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Page MJ, McKenzie JE, Bossuyt PM, et al. BMJ. 2021;372:0.
    1. Evaluating non-randomised intervention studies. Deeks JJ, Dinnes J, D'Amico R, et al. Health Technol Assess. 2003;7:1–173.
    1. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS) Downes MJ, Brennan ML, Williams HC, Dean RS. BMJ Open. 2016;6:0.
    1. Placental syndecan-1 and sulphated glycosaminoglycans are decreased in preeclampsia. Heyer-Chauhan N, Ovbude IJ, Hills AA, Sullivan MH, Hills FA. J Perinat Med. 2014;42:329–338.
    1. Early onset preeclampsia is associated with glycocalyx degradation and reduced microvascular perfusion. Weissgerber TL, Garcia-Valencia O, Milic NM, et al. J Am Heart Assoc. 2019;8:0.
    1. Soluble syndecan-1 and glycosaminoglycans in preeclamptic and normotensive pregnancies. Hassani Lahsinoui H, Amraoui F, Spijkers LJ, et al. Sci Rep. 2021;11:4387.
    1. Evaluation of syndecan-1 as a novel biomarker for adverse pregnancy outcomes. Greeley ET, Rochelson B, Krantz DA, et al. Reprod Sci. 2020;27:355–363.
    1. Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study. Kuessel L, Husslein H, Montanari E, et al. Clin Chem Lab Med. 2019;58:50–58.
    1. Levels of syndecan-1 and hyaluronan in early- and late-onset preeclampsia. Kornacki J, Wirstlein P, Wender-Ozegowska E. Pregnancy Hypertens. 2019;18:108–111.
    1. Chronic hypertension in pregnancy: impact of ethnicity and superimposed preeclampsia on placental, endothelial, and renal biomarkers. Webster LM, Gill C, Seed PT, et al. Am J Physiol Regul Integr Comp Physiol. 2018;315:0–47.
    1. Evaluation of maternal serum hypoxia inducible factor-1α, progranulin and syndecan-1 levels in pregnancies with early- and late-onset preeclampsia. Alici Davutoğlu E, Akkaya Firat A, Ozel A, Yılmaz N, Uzun I, Temel Yuksel I, Madazlı R. J Matern Fetal Neonatal Med. 2018;31:1976–1982.
    1. Low soluble syndecan-1 precedes preeclampsia. Gandley RE, Althouse A, Jeyabalan A, et al. PLoS One. 2016;11:0.
    1. Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. Szabo S, Xu Y, Romero R, et al. Virchows Arch. 2013;463:445–458.
    1. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Phipps E, Prasanna D, Brima W, Jim B. Clin J Am Soc Nephrol. 2016;11:1102–1113.
    1. Pre-eclampsia. Chappell LC, Cluver CA, Kingdom J, Tong S. Lancet. 2021;398:341–354.
    1. Latest advances in understanding preeclampsia. Redman CW, Sargent IL. Science. 2005;308:1592–1594.
    1. Syndecan-regulated receptor signaling. Rapraeger AC. J Cell Biol. 2000;149:995–998.
    1. Syndecans: new kids on the signaling block. Tkachenko E, Rhodes JM, Simons M. Circ Res. 2005;96:488–500.
    1. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Lamorte S, Ferrero S, Aschero S, et al. Leukemia. 2012;26:1081–1090.
    1. Increased serum concentrations of circulating glycocalyx components in HELLP syndrome compared to healthy pregnancy: an observational study. Hofmann-Kiefer KF, Knabl J, Martinoff N, et al. Reprod Sci. 2013;20:318–325.
    1. Preeclampsia leads to dysregulation of various signaling pathways in placenta. Kang JH, Song H, Yoon JA, et al. J Hypertens. 2011;29:928–936.
    1. Placental expression of syndecan 1 is diminished in preeclampsia. Jokimaa VI, Kujari HP, Ekholm EM, Inki PL, Anttila L. Am J Obstet Gynecol. 2000;183:1495–1498.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever